Demographics of OCD and Effective Treatment: Brief Report

minority groups [7] understanding what factors (i.e. cost, stigma, religious beliefs, racism, demographic locations) are creating treatment resistance may assist in addressing these barriers by providing more knowledge to the public about these treatment inefficiencies. One study evaluating 166 college students found that Caucasians attended a much greater degree of therapy sessions than those of African American, Asian American, and Latino descents. Obsessive-Compulsive Disorder is a common and disabling disorder that is undertreated among all ethnicities [8] and many countries do not Abstract Obsessive-Compulsive Disorder (OCD) is a common and debilitating disorder that worsens without appropriate treatment. Due to stigma, lack of resources, demographics, and cultural bias many individuals are not receiving appropriate care. The aim of this study was to examine treatment disparities based on geographic locations. Results from this study found that Exposure and Response Prevention (ERP) was more likely to be used with individuals living in the United States and Australia than those living in Asia and India. Additionally, individuals living in the United States, South and Central America were more likely to take medication for OCD. Results also revealed that individuals living in the United Kingdom were less likely to try medication. These results highlight the need for education at a global level around effective treatment for OCD.


Introduction
Obsessive-Compulsive Disorder (OCD) is a severe and disabling mental illness that worsens over time without effective treatment.

Evidence based Exposure and Response Prevention (ERP) in combination with medication management of Selective Serotonin
Reuptake Inhibitors (SSRIs) is the preferred treatment for OCD [1].
The lifetime prevalence of OCD is approximately 2-3% of the general population [1] which translates to roughly 200 million people globally. It takes an average of 17 years for an individual to receive appropriate treatment (i.e. ERP and medication management) from the onset of symptoms (Jenike, 2004). The prevalence rates of OCD among ethnic minorities are similar across the board, however there is a clear underrepresentation of mental health services among ethnic minorities [2]. Ethnic minorities are less likely to receive adequate treatment for OCD due to a wide range of factors including low income, racism, stigma surrounding mental health, family factors, and cultural differences [3,4]. Acknowledging the specific barriers in treatment amongst ethnicities will provide a focus for what disparities need to be addressed [5]. Asian Americans and Pacific Islanders use mental health services less frequently than any other minority [6].
Additionally, African Americans, Latinos, Asian Americans, and Native Americans are more likely to drop out of treatment prematurely; additionally, African Americans and Latin Americans are less likely to be prescribed medications [5]. When accounting for consistent OCD prevalence rates globally and across all minority groups [7] understanding what factors (i.e. cost, stigma, religious beliefs, racism, demographic locations) are creating treatment resistance may assist in addressing these barriers by providing more knowledge to the public about these treatment inefficiencies.
One study evaluating 166 college students found that Caucasians attended a much greater degree of therapy sessions than those of African American, Asian American, and Latino descents. Obsessive-Compulsive Disorder is a common and disabling disorder that is undertreated among all ethnicities [8] and many countries do not have adequate treatment readily available for those suffering with OCD or related disorders [9].
When considering ethnic minorities, having a diagnosis of OCD is in proportion to the general population [2] however access to and utilization of treatment varies greatly. Understanding the specific treatment disparities related to OCD globally will allow for enhancements to education and awareness in order to lessen this gap. The purpose of this paper is to evaluate users of a self-help OCD website to better understand minority's access to and utilization of psychological and pharmacological treatment for OCD.

Method
The present study included 2094 participants ranging from 7 to 77 years of age (M = 30.98, SD = 12.06). Participant data used for this study was de-identified data from the OCD Challenge website  .007]. More specifically, participants living in Australia were more likely to report participating in ERP, while participants living in India and Asia were more likely to report they had not.

Results revealed a significant association between country
Finally, results revealed there was no association between country of residence and whether someone was currently taking medication [χ 2 (9) = 12.17; p = .204] or whether they had never taken medication [χ 2 (9) = 14.81; p = .096].

Discussion
Findings from this study further confirm treatment disparities for OCD that exist based on geographic location. Results indicate that individuals who in the United States, Central and South America were more likely to report past medication use for OCD while individuals in the UK were more likely to report they had not taken medication in the past. Despite this finding, results revealed no association among geographic location and current medication use. Results identified that individuals in Australia were more likely to have engaged in ERP and individuals in Asia and India were more likely to report they had not engaged in ERP treatment, revealing a treatment disparity among country of residence. These findings are limited due to both our sample size and nature of our sample. Individuals from this sample voluntarily accessed a selfhelp website for OCD without a screening metric. Further research should appropriately screen/diagnose OCD and replicate these demographics to confirm study findings.
We know that a treatment gap of 58.2% exists for OCD in the Americas [10], further indicating that other countries with less treatment engagement may have even higher treatment gaps. This study confirms disparities relating to medication management and ERP for OCD. Medication is utilized to a lessened degree outside of the Americas while ERP is underutilized in Asia and India.
Although our findings suggest that Australians may be most likely to have received ERP previously, further research should confirm this finding. We know that OCD prevalence rates remain the same across the globe yet both access to treatment and treatment utilization varies significantly. These findings further corroborate the need for global access to evidence based treatment for OCD, which is recognized as the combination of medication and ERP, in order to lessen the gap across the globe between those diagnosed with OCD and those receiving evidence-based care.